Epidemiology, comorbidity, and use of systemic therapies in patients with paediatric psoriasis in Germany

被引:0
|
作者
Biermann, Mona [1 ,2 ]
Kolb, Benjamin [1 ]
机构
[1] Novartis Pharm GmbH, Nurnberg, Germany
[2] Novartis Pharma GmbH, Roonstr 25, D-90429 Nurnberg, Germany
关键词
Paediatric psoriasis; Systemic therapy; Comorbidity; Germany; CHILDHOOD PSORIASIS; CHILDREN; ADOLESCENTS; SAFETY; ETANERCEPT; PREVALENCE; EFFICACY; DISEASES;
D O I
10.1016/j.zefq.2023.10.004
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: Psoriasis is a chronic, inflammatory disorder with a physical and psychosocial burden. Recent epidemiological data on paediatric psoriasis in Germany is lacking. The aim of this study was to examine the prevalence, the incidence and associated epidemiological features of paediatric psoriasis in Germany using health claims data from a national health claims database.Methods: Continuously insured patients with paediatric psoriasis (2014-2017) from the Institute of Applied Health Research Berlin (InGef) database were included in this analysis. Between 2014 and 2017, we analysed the prevalence and incidence of paediatric psoriasis (aged < 17 years), relevant comorbidities, the most frequently attended and diagnosing medical specialties, and the number of systemic treatment prescriptions.Results: Overall, psoriasis prevalence (0.15-0.16%) and incidence (0.06-0.07%) remained stable between 2014 and 2017; both prevalence and incidence were higher in female patients. Psoriasis prevalence gradually increased with age between the age groups <6 years and 16-17 years. Obesity (11.5%) and somato-form disorders (7.0%) were the most common comorbidities identified. Overall, 90.4% of the psoriasis cases were diagnosed by either a dermatologist (50.9%), general practitioner (27.8%), or paediatrician (11.7%). Patients most frequently attended general practitioners (74.5%), dermatologists (57.9%) and paediatricians (56.5%). The use of systemic treatment(s) increased from 4.7% to 5.4% between 2014 and 2017.Discussion: The prevalence and incidence of paediatric psoriasis in Germany remained stable between 2014 and 2017, with a higher prevalence and incidence observed in females and older adolescents. Obesity and somatoform disorders were the most common comorbidities. General practitioners, dermatologists, and paediatricians were most often involved in the treatment of patients, highlighting the need for interdisciplinary management of paediatric psoriasis.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 50 条
  • [1] Epidemiology and comorbidity of juvenile psoriasis vulgaris in Germany
    Augustin, M.
    Schaefer, I.
    Reich, K.
    Radtke, M. A.
    Glaeske, G.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2009, 7 : 196 - 196
  • [2] Epidemiology and comorbidity of psoriasis in children
    Augustin, M.
    Glaeske, G.
    Radtke, M. A.
    Christophers, E.
    Reich, K.
    Schaefer, I.
    BRITISH JOURNAL OF DERMATOLOGY, 2010, 162 (03) : 633 - 636
  • [3] Epidemiology and comorbidity of obesity in Germany
    Bramlage, P.
    DIABETOLOGE, 2008, 4 (04): : 259 - +
  • [4] Epidemiology of mental health comorbidity in psoriasis
    Wu, J. J.
    Feldman, S. R.
    Koo, J.
    Marangell, L. B.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (05) : 487 - 495
  • [5] Transitioning patients with psoriasis from conventional systemic psoriasis therapies to alefacept
    Cather, J
    Meier, A
    Young, M
    Menter, A
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P200 - P200
  • [6] Epidemiology and Drug Supply for juvenile Psoriasis Patients in Germany
    Radtke, M. A.
    Schaefer, I
    Kaempfe, S.
    Glaeske, G.
    Augustin, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 99 - 99
  • [7] Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences
    Boehncke, Wolf-Henning
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [8] The Use of Microbial Modifying Therapies to Prevent Psoriasis Exacerbation and Associated Cardiovascular Comorbidity
    Eva Reali
    Cristiana Caliceti
    Antonello Lorenzini
    Paola Rizzo
    Inflammation, 2024, 47 : 13 - 29
  • [9] The Use of Microbial Modifying Therapies to Prevent Psoriasis Exacerbation and Associated Cardiovascular Comorbidity
    Reali, Eva
    Caliceti, Cristiana
    Lorenzini, Antonello
    Rizzo, Paola
    INFLAMMATION, 2024, 47 (01) : 13 - 29
  • [10] Use of systemic therapies for psoriasis in the COVID-19 era
    Kearns, Donovan G.
    Uppal, Shelley
    Chat, Vipawee S.
    Wu, Jashin J.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 622 - 625